Summit Therapeutics PLC (SMMT) - Total Liabilities
Based on the latest financial reports, Summit Therapeutics PLC (SMMT) has total liabilities worth $69.47 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Summit Therapeutics PLC cash flow conversion to assess how effectively this company generates cash.
Summit Therapeutics PLC - Total Liabilities Trend (2003–2024)
This chart illustrates how Summit Therapeutics PLC's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Summit Therapeutics PLC to evaluate the company's liquid asset resilience ratio.
Summit Therapeutics PLC Competitors by Total Liabilities
The table below lists competitors of Summit Therapeutics PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Dr. Reddy’s Laboratories Ltd ADR
NYSE:RDY
|
USA | $179.92 Billion |
|
Kerry Group
IR:KRZ
|
Ireland | €5.73 Billion |
|
Pinnacle West Capital Corp
NYSE:PNW
|
USA | $22.68 Billion |
|
Jack Henry & Associates Inc
NASDAQ:JKHY
|
USA | $856.99 Million |
|
Ivanhoe Mines Ltd.
TO:IVN
|
Canada | CA$1.76 Billion |
|
Service Corporation International
NYSE:SCI
|
USA | $17.02 Billion |
Liability Composition Analysis (2003–2024)
This chart breaks down Summit Therapeutics PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Summit Therapeutics PLC (SMMT) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.80 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.27 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Summit Therapeutics PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Summit Therapeutics PLC (2003–2024)
The table below shows the annual total liabilities of Summit Therapeutics PLC from 2003 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $46.81 Million | -62.63% |
| 2023-12-31 | $125.26 Million | -76.70% |
| 2022-12-31 | $537.51 Million | +1686.35% |
| 2021-12-31 | $30.09 Million | +30.57% |
| 2020-12-31 | $23.05 Million | +60.69% |
| 2019-12-31 | $14.34 Million | -36.52% |
| 2018-12-31 | $22.59 Million | -63.80% |
| 2017-12-31 | $62.40 Million | +21.53% |
| 2016-12-31 | $51.35 Million | +814.38% |
| 2015-12-31 | $5.62 Million | -15.87% |
| 2014-12-31 | $6.67 Million | +116.50% |
| 2013-12-31 | $3.08 Million | +27.91% |
| 2012-12-31 | $2.41 Million | +3.02% |
| 2011-12-31 | $2.34 Million | +4.64% |
| 2010-12-31 | $2.24 Million | -56.61% |
| 2009-12-31 | $5.15 Million | -33.65% |
| 2008-12-31 | $7.77 Million | -49.24% |
| 2007-12-31 | $15.30 Million | +141.81% |
| 2006-12-31 | $6.33 Million | +154.11% |
| 2005-12-31 | $2.49 Million | +611.07% |
| 2004-12-31 | $350.21K | +9497.48% |
| 2003-12-31 | $3.65K | -- |
About Summit Therapeutics PLC
Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small… Read more